CompletedNot applicableNCT01872819

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Washington
Principal Investigator: Pamela Becker
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Intervention: antitumor drug screening assay(other)
Enrollment: 16 enrolled
Eligibility: 18 years · All sexes
Timeline: 2013 – 2014

Study locations (1)

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01872819 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials